NBIX — NEUROCRINE BIOSCIENCES INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 914475 ·
Last close
$166.80
Market Cap
$16.77B
52W High
$186.12
52W Low
$129.86
ADV30
1,336,473
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 814,500,000 | 800,700,000 | 186,000,000 | 197,900,000 | 4,906,200,000 | 266,500,000 | 1,498,800,000 |
| Dec 2025 | 805,500,000 | 787,900,000 | 227,900,000 | 153,700,000 | 4,631,500,000 | 713,000,000 | 1,378,400,000 |
| Sep 2025 | 794,900,000 | 780,900,000 | 239,300,000 | 209,500,000 | 4,265,700,000 | 340,200,000 | 1,262,100,000 |
| Jun 2025 | 687,500,000 | 676,200,000 | 145,600,000 | 107,500,000 | 3,889,800,000 | 264,000,000 | 1,195,500,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$863,700,000
Investing CF
$-784,800,000
Financing CF
$-6,500,000
CapEx
$-45,500,000
Dividends Paid
—
Buybacks
$-71,700,000
EPS Diluted TTM
$6.49
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$589,600,000
Inventory
$64,500,000
Receivables
$768,100,000
ST Investments
$1,049,700,000
EBIT TTM
$798,800,000
Pretax Income TTM
$937,500,000
Interest Exp TTM
—
Analysts
27
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,373,900,032
EBITDA
$836,000,000
Free Cash Flow
$590,550,016
Enterprise Value
$18,747,500,544
Total Cash
$389,800,000
Total Debt
$401,800,000
Shares Out
100,549,983
Trailing EPS
$6.85
Book Value
$33.87
ROE
22.1%
ROA
10.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,860,500,000 | 636,500,000 | 478,600,000 | 4,631,500,000 | 1,378,400,000 | — | 782,700,000 |
| Dec 2024 | 2,355,300,000 | 583,000,000 | 341,300,000 | 3,718,700,000 | 1,129,000,000 | — | 595,400,000 |
| Dec 2023 | 1,887,100,000 | 394,800,000 | 249,700,000 | 3,251,400,000 | 1,019,400,000 | — | 389,900,000 |
| Dec 2022 | 1,488,700,000 | 249,000,000 | 154,500,000 | 2,368,700,000 | 660,900,000 | — | 339,400,000 |
TTM Snapshot
Revenues TTM
$1,804,800,000
NetIncome TTM
$303,900,000
OpCashFlow TTM
$0
Assets (Latest)
$3,718,700,000
Forward EPS
$12.66
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EXEL | EXELIXIS, INC. | $13.33B | $53.03 | — |
| MRNA | Moderna, Inc. | $21.75B | $54.82 | — |
| BNTX | BioNTech SE | $22.91B | $90.58 | — |
| TECH | BIO-TECHNE Corp | $11.23B | $72.09 | — |
| KRYS | Krystal Biotech, Inc. | $10.06B | $341.12 | — |
News headlines (Yahoo Finance, 1h cache)
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
2026-07-31 16:17 · Yahoo
NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives Growth
2026-07-31 14:00 · Yahoo
Neurocrine Biosciences Inc (NBIX) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...
2026-07-31 05:05 · Yahoo
Neurocrine Biosciences, Inc. Q2 2026 Earnings Call Summary
2026-07-31 02:53 · Yahoo
Neurocrine (NBIX) Q2 2026 Earnings Call Transcript
2026-07-31 01:47 · Yahoo
Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say
2026-07-30 21:30 · Yahoo
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
2026-07-30 21:15 · Yahoo
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
2026-07-30 20:01 · Yahoo
CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised
2026-07-30 16:02 · Yahoo
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
2026-07-30 14:58 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.